


ABSTRACTSUBSTITUTED TETRAHYDROISOQUINOLINES

- 5 The invention is directed to physiologically active compounds of formula (I):-



(I)

wherein:-

- 10 R¹ represents optionally substituted aryl, optionally substituted heteroaryl, R³NH-Ar¹-L²- or R³-NH-C(=O)-NH-Ar²-L²-; R³ represents aryl or heteroaryl; Ar¹ represents a saturated, partially saturated or fully unsaturated 8- to 10-membered bicyclic ring system containing at least one heteroatom selected from O, S or N; Ar² represents aryldiyl or heteroaryldiyl; L¹ represents a linkage, such as an alkylene linkage; L² represents an alkylene chain linkage; R² represents hydrogen, halogen, C₁-₄alkyl or
- 15 C₁-₄alkoxy; and Y is carboxy or an acid bioisostere;
- but excluding compounds where an oxygen, nitrogen or sulfur atom is attached directly to a carbon carbon multiple bond of an alkenylene or alkynylene residue;
- and the corresponding N-oxides and ester prodrugs thereof, and the pharmaceutically acceptable salts and solvates of such compounds, and the N-oxides and ester prodrugs thereof.
- 20 Such compounds have valuable pharmaceutical properties, in particular the ability to regulate the interaction of VCAM-1 and fibronectin with the integrin VLA-4 (α4β1).